HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Arndt Hartmann Selected Research

Estrogen Receptor alpha

1/2022High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
5/2014The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.
10/2013Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer.
3/2009Correlation of body mass index and menopausal status with the intra-tumoral estrogen system in invasive breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Arndt Hartmann Research Topics

Disease

321Neoplasms (Cancer)
05/2024 - 03/2002
100Carcinoma (Carcinomatosis)
03/2024 - 05/2002
86Breast Neoplasms (Breast Cancer)
04/2024 - 01/2004
80Urinary Bladder Neoplasms (Bladder Cancer)
01/2024 - 03/2002
54Renal Cell Carcinoma (Grawitz Tumor)
12/2023 - 03/2003
30Prostatic Neoplasms (Prostate Cancer)
05/2024 - 04/2005
30Neoplasm Metastasis (Metastasis)
02/2024 - 09/2004
25Colorectal Neoplasms (Colorectal Cancer)
01/2023 - 09/2004
20Non-Muscle Invasive Bladder Neoplasms
02/2024 - 05/2012
19Carcinogenesis
01/2019 - 11/2002
15Colonic Neoplasms (Colon Cancer)
05/2023 - 09/2004
13Microsatellite Instability
05/2024 - 02/2003
13Inflammation (Inflammations)
10/2023 - 03/2010
12Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2023 - 01/2006
11Squamous Cell Carcinoma of Head and Neck
01/2024 - 01/2006
11Triple Negative Breast Neoplasms
01/2024 - 06/2017
11Rectal Neoplasms (Rectal Cancer)
01/2023 - 02/2012
11Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 05/2007
10Adenocarcinoma
04/2023 - 01/2008
10Lymphatic Metastasis
02/2021 - 05/2008
9Sarcoma (Soft Tissue Sarcoma)
02/2024 - 06/2014
8Lung Neoplasms (Lung Cancer)
11/2023 - 05/2007
8Margins of Excision
01/2022 - 06/2009
8Disease Progression
11/2020 - 04/2010
7Adenocarcinoma of Lung
07/2023 - 12/2014
7Hypoxia (Hypoxemia)
01/2022 - 04/2009
7Melanoma (Melanoma, Malignant)
01/2021 - 04/2005
7Hepatocellular Carcinoma (Hepatoma)
01/2018 - 05/2005
6Ulcerative Colitis
01/2024 - 09/2010
6Ovarian Neoplasms (Ovarian Cancer)
01/2023 - 03/2007
6Adenoma (Adenomas)
04/2016 - 04/2007
5Necrosis
05/2023 - 04/2005
5Leiomyomatosis
11/2020 - 01/2013
4Kidney Neoplasms (Kidney Cancer)
12/2023 - 01/2013
4COVID-19
01/2023 - 03/2021
4Noninfiltrating Intraductal Carcinoma (DCIS)
10/2022 - 11/2007

Drug/Important Bio-Agent (IBA)

122Proteins (Proteins, Gene)FDA Link
03/2024 - 11/2002
68Biomarkers (Surrogate Marker)IBA
05/2024 - 01/2008
60Messenger RNA (mRNA)IBA
04/2023 - 10/2003
37ParaffinIBA
01/2023 - 08/2002
34Phenobarbital (Luminal)FDA Link
03/2024 - 01/2007
32DNA (Deoxyribonucleic Acid)IBA
01/2023 - 08/2002
31Formaldehyde (Formol)FDA Link
01/2023 - 04/2005
27Hormones (Hormone)IBA
04/2024 - 11/2008
27RNA (Ribonucleic Acid)IBA
02/2024 - 10/2003
24Immune Checkpoint InhibitorsIBA
05/2024 - 11/2016
15Estrogen ReceptorsIBA
01/2023 - 12/2008
15MicroRNAs (MicroRNA)IBA
11/2022 - 04/2010
14B7-H1 AntigenIBA
04/2024 - 01/2016
14Transcription Factors (Transcription Factor)IBA
02/2024 - 11/2008
14Progesterone Receptors (Progesterone Receptor)IBA
01/2023 - 11/2009
10Cadherins (E-Cadherin)IBA
01/2024 - 02/2009
10AntibodiesIBA
05/2023 - 01/2006
9PlatinumIBA
04/2022 - 03/2007
9Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA
01/2021 - 08/2007
9Codon (Codons)IBA
01/2018 - 05/2002
8Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2024 - 08/2006
8Indicators and Reagents (Reagents)IBA
11/2023 - 01/2004
8Cisplatin (Platino)FDA LinkGeneric
04/2021 - 08/2010
8AcidsIBA
11/2017 - 03/2002
7ErbB Receptors (EGF Receptor)IBA
04/2024 - 01/2006
7LigandsIBA
01/2024 - 02/2015
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2023 - 02/2013
7pembrolizumabIBA
05/2023 - 01/2019
7Estrogens (Estrogen)FDA Link
01/2023 - 11/2008
7HLA-G Antigens (HLA G)IBA
11/2022 - 06/2015
7Keratins (Keratin)IBA
02/2022 - 03/2011
7Androgen Receptors (Androgen Receptor)IBA
06/2021 - 06/2017
6Tyrosine Kinase InhibitorsIBA
12/2023 - 06/2014
6HLA Antigens (Human Leukocyte Antigens)IBA
01/2022 - 04/2012
6Fumarate Hydratase (Fumarase)IBA
11/2020 - 01/2016
6Protein Isoforms (Isoforms)IBA
01/2020 - 04/2009
5Immunoconjugates (Immunoconjugate)IBA
04/2024 - 12/2021
5Fluorouracil (Carac)FDA LinkGeneric
05/2023 - 05/2006
5Programmed Cell Death 1 ReceptorIBA
01/2023 - 01/2016
5trans-sodium crocetinate (crocetin)IBA
10/2022 - 11/2021
5Sucrose (Saccharose)IBA
01/2018 - 08/2015
5Carrier Proteins (Binding Protein)IBA
08/2017 - 06/2011
5WD repeat containing planar cell polarity effectorIBA
10/2015 - 04/2004
5SERPIN-B5 (maspin)IBA
05/2012 - 04/2005
5Complementary DNA (cDNA)IBA
06/2009 - 04/2004
4Phosphotransferases (Kinase)IBA
04/2024 - 01/2004
4enfortumab vedotinIBA
04/2024 - 01/2023
4C-Reactive ProteinIBA
11/2023 - 11/2019
4LipidsIBA
10/2023 - 03/2010
4Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
07/2023 - 08/2009
4InterferonsIBA
01/2023 - 01/2008
4AntigensIBA
11/2022 - 01/2018

Therapy/Procedure

113Therapeutics
04/2024 - 12/2003
43Drug Therapy (Chemotherapy)
01/2023 - 12/2003
33Cystectomy
02/2024 - 11/2002
28Immunotherapy
05/2024 - 04/2010
24Neoadjuvant Therapy
01/2024 - 02/2011
13Lasers (Laser)
01/2023 - 12/2002
13Adjuvant Chemotherapy
08/2022 - 08/2010
12Chemoradiotherapy
01/2023 - 02/2012
9Radiotherapy
01/2023 - 12/2003
9Prostatectomy (Retropubic Prostatectomy)
07/2015 - 11/2008
7Aftercare (After-Treatment)
09/2022 - 04/2004
6Transurethral Resection of Bladder
02/2024 - 07/2017